{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.14","upperLimit":"18.14","value":"12.57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Number of weeks from the date of first dose of study treatment to the date of death from any cause, estimated using KM methods with 95% CIs for subjects in the SAF. Subjects without documentation of death at the time of analysis were censored as of the date the subject was last known to be alive, or the data cut-off date, whichever is earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"CRS-207 and pembrolizumab were administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) was administered by IV infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 CFU) was administered by IV infusion over 1 hour on Day 2. If tolerated, pembrolizumab and CRS-207 were administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab continued to be administered on Day 1 at each treatment cycle (every 3 weeks); and CRS-207 was administered once every 6 weeks (every other cycle).","id":"OG000","title":"Experimental"}],"paramType":"MEDIAN","populationDescription":"Analysis of OS was performed on subjects in the SAF.","reportingStatus":"POSTED","timeFrame":"OS was assessed from the first dose of study treatment until death or study termination, whichever is earlier, assessed up to 25 weeks.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"weeks"}